AG˹ٷ

STOCK TITAN

[Form 4] Sprout Social, Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Monopar Therapeutics (MNPR) � Form 4 insider transaction filed for Chief Operating Officer Andrew Cittadine covering activity on 30 June 2025.

  • 6,863 common shares were issued to Cittadine upon the vesting of Restricted Stock Units (RSUs) granted on 2 Feb 2022, 1 Feb 2023 and 4 Mar 2025.
  • 2,990 shares were withheld for taxes (transaction code “F�), leaving a net 3,873 new shares.
  • Cittadine’s direct common-stock holding after the transactions is 45,858 shares; he also retains 43,001 unvested RSUs.
  • No open-market purchases or sales occurred; all activity relates to automatic RSU settlement (transaction code “M�).

The filing indicates a routine equity-compensation event rather than a discretionary purchase. While the COO’s ownership stake increases modestly, the economic outlay is zero; therefore, the signal for outside investors is generally neutral.

Monopar Therapeutics (MNPR) � Transazione interna Form 4 presentata per il Chief Operating Officer Andrew Cittadine relativa all'attività del 30 giugno 2025.

  • Sono state emesse 6.863 azioni ordinarie a favore di Cittadine in seguito al vesting delle Restricted Stock Units (RSU) concesse il 2 feb 2022, 1 feb 2023 e 4 mar 2025.
  • Sono state trattenute 2.990 azioni per tasse (codice transazione “F�), lasciando un netto di 3.873 nuove azioni.
  • Il possesso diretto di azioni ordinarie di Cittadine dopo le transazioni è di 45.858 azioni; mantiene inoltre 43.001 RSU non ancora vestite.
  • Non si sono verificate compravendite sul mercato aperto; tutta l'attività riguarda il regolamento automatico delle RSU (codice transazione “M�).

La comunicazione indica un evento di compensazione azionaria di routine piuttosto che un acquisto discrezionale. Sebbene la quota di proprietà del COO aumenti leggermente, il costo economico è nullo; pertanto, il segnale per gli investitori esterni è generalmente neutrale.

Monopar Therapeutics (MNPR) � Transacción interna Formulario 4 presentada para el Director de Operaciones Andrew Cittadine correspondiente a la actividad del 30 de junio de 2025.

  • Se emitieron 6,863 acciones comunes a Cittadine tras el vesting de Unidades de Acciones Restringidas (RSU) otorgadas el 2 de feb de 2022, 1 de feb de 2023 y 4 de mar de 2025.
  • 2,990 acciones fueron retenidas para impuestos (código de transacción “F�), quedando un neto de 3,873 nuevas acciones.
  • La tenencia directa de acciones comunes de Cittadine tras las transacciones es de 45,858 acciones; además mantiene 43,001 RSU no adquiridas.
  • No hubo compras o ventas en el mercado abierto; toda la actividad se relaciona con la liquidación automática de RSU (código de transacción “M�).

La presentación indica un evento rutinario de compensación accionaria más que una compra discrecional. Aunque la participación del COO aumenta modestamente, el gasto económico es cero; por lo tanto, la señal para los inversores externos es generalmente neutral.

Monopar Therapeutics (MNPR) � 내부� 거래 Form 4가 최고운영책임� Andrew Cittadine� 위해 2025� 6� 30� 활동� 대상으� 제출되었습니�.

  • 6,863 보통�가 2022� 2� 2�, 2023� 2� 1�, 2025� 3� 4일에 부여된 제한 주식 단위(RSU)� 베스�(권리 확정)� 따라 Cittadine에게 발행되었습니�.
  • 2,990 주식세금 원천징수(거래 코드 “F�)� 위해 보류되어 � 3,873 주식� 남았습니�.
  • 거래 � Cittadine� 직접 보유 보통주 45,858 �이며, 43,001개의 베스팅되지 않은 RSU� 보유하고 있습니다.
  • 시장 � 매매� 없었으며, 모든 활동은 자동 RSU 정산(거래 코드 “M�)� 관련되� 있습니다.

이번 제출은 임의 매수가 아닌 정기적인 주식 보상 이벤트임� 나타냅니�. COO� 지분이 소폭 증가했으� 경제� 지출은 전혀 �으므� 외부 투자자에� 주 신호� 대체로 중립�입니�.

Monopar Therapeutics (MNPR) � Transaction d'initié Formulaire 4 déposée pour le Directeur des opérations Andrew Cittadine concernant l'activité du 30 juin 2025.

  • 6 863 actions ordinaires ont été attribuées à Cittadine lors du vesting des Restricted Stock Units (RSU) accordées les 2 février 2022, 1 février 2023 et 4 mars 2025.
  • 2 990 actions ont été retenues pour impôts (code transaction « F »), laissant un net de 3 873 nouvelles actions.
  • La détention directe d'actions ordinaires de Cittadine après les transactions est de 45 858 actions ; il conserve également 43 001 RSU non acquises.
  • Aucun achat ou vente sur le marché ouvert n'a eu lieu ; toute l'activité concerne le règlement automatique des RSU (code transaction « M »).

Le dépôt indique un événement de rémunération en actions de routine plutôt qu'un achat discrétionnaire. Bien que la participation du COO augmente modestement, la dépense économique est nulle ; par conséquent, le signal pour les investisseurs externes est généralement neutre.

Monopar Therapeutics (MNPR) � Form 4 Insider-Transaktion eingereicht für Chief Operating Officer Andrew Cittadine bezüglich der Aktivität am 30. Juni 2025.

  • 6.863 Stammaktien wurden Cittadine bei der Vesting von Restricted Stock Units (RSUs) zugeteilt, die am 2. Feb 2022, 1. Feb 2023 und 4. März 2025 gewährt wurden.
  • 2.990 Aktien wurden zur Steuerabführung einbehalten (Transaktionscode „F�), wodurch netto 3.873 neue Aktien verbleiben.
  • Cittadines direkter Stammaktienbestand nach den Transaktionen beträgt 45.858 Aktien; er hält zudem 43.001 unverfallbare RSUs.
  • Es fanden keine Käufe oder Verkäufe am offenen Markt statt; alle Aktivitäten beziehen sich auf die automatische RSU-Abwicklung (Transaktionscode „M�).

Die Meldung weist auf ein routinemäßiges Aktienvergütungsereignis hin und nicht auf einen diskretionären Kauf. Obwohl der Anteil des COO leicht steigt, ist der wirtschaftliche Aufwand null; daher ist das Signal für externe Investoren im Allgemeinen neutral.

Positive
  • COO’s direct ownership increased, modestly reinforcing management-shareholder alignment.
Negative
  • Shares were acquired via vesting, not open-market purchase, so the transaction conveys limited confidence signal.

Insights

TL;DR: Routine RSU vesting—neutral cash-less insider acquisition, minor ownership increase.

The 6,863-share issuance stems from pre-scheduled RSU tranches. Net of tax withholding, Cittadine adds 3,873 shares, taking his direct stake to 45,858 (�0.4 % of ~11 m shares outstanding). The insider neither paid cash nor sold shares, limiting signaling value. The remaining 43,001 RSUs provide further equity alignment but already factored into fully-diluted share count. Overall impact on valuation, liquidity, or float is immaterial; I classify as neutral.

TL;DR: Equity compensation schedule functioning as designed; governance implications minimal.

The staggered 48-month RSU schedules (2022�2028) support retention of key executives and align incentives without immediate cash cost. Transaction codes “M� and “F� confirm automatic settlement and tax withholding compliance. No 10b5-1 plan is referenced, but the absence of discretionary trades limits potential conflicts. Because the event is routine and disclosed timely, governance risk remains low; therefore, I assign a neutral impact.

Monopar Therapeutics (MNPR) � Transazione interna Form 4 presentata per il Chief Operating Officer Andrew Cittadine relativa all'attività del 30 giugno 2025.

  • Sono state emesse 6.863 azioni ordinarie a favore di Cittadine in seguito al vesting delle Restricted Stock Units (RSU) concesse il 2 feb 2022, 1 feb 2023 e 4 mar 2025.
  • Sono state trattenute 2.990 azioni per tasse (codice transazione “F�), lasciando un netto di 3.873 nuove azioni.
  • Il possesso diretto di azioni ordinarie di Cittadine dopo le transazioni è di 45.858 azioni; mantiene inoltre 43.001 RSU non ancora vestite.
  • Non si sono verificate compravendite sul mercato aperto; tutta l'attività riguarda il regolamento automatico delle RSU (codice transazione “M�).

La comunicazione indica un evento di compensazione azionaria di routine piuttosto che un acquisto discrezionale. Sebbene la quota di proprietà del COO aumenti leggermente, il costo economico è nullo; pertanto, il segnale per gli investitori esterni è generalmente neutrale.

Monopar Therapeutics (MNPR) � Transacción interna Formulario 4 presentada para el Director de Operaciones Andrew Cittadine correspondiente a la actividad del 30 de junio de 2025.

  • Se emitieron 6,863 acciones comunes a Cittadine tras el vesting de Unidades de Acciones Restringidas (RSU) otorgadas el 2 de feb de 2022, 1 de feb de 2023 y 4 de mar de 2025.
  • 2,990 acciones fueron retenidas para impuestos (código de transacción “F�), quedando un neto de 3,873 nuevas acciones.
  • La tenencia directa de acciones comunes de Cittadine tras las transacciones es de 45,858 acciones; además mantiene 43,001 RSU no adquiridas.
  • No hubo compras o ventas en el mercado abierto; toda la actividad se relaciona con la liquidación automática de RSU (código de transacción “M�).

La presentación indica un evento rutinario de compensación accionaria más que una compra discrecional. Aunque la participación del COO aumenta modestamente, el gasto económico es cero; por lo tanto, la señal para los inversores externos es generalmente neutral.

Monopar Therapeutics (MNPR) � 내부� 거래 Form 4가 최고운영책임� Andrew Cittadine� 위해 2025� 6� 30� 활동� 대상으� 제출되었습니�.

  • 6,863 보통�가 2022� 2� 2�, 2023� 2� 1�, 2025� 3� 4일에 부여된 제한 주식 단위(RSU)� 베스�(권리 확정)� 따라 Cittadine에게 발행되었습니�.
  • 2,990 주식세금 원천징수(거래 코드 “F�)� 위해 보류되어 � 3,873 주식� 남았습니�.
  • 거래 � Cittadine� 직접 보유 보통주 45,858 �이며, 43,001개의 베스팅되지 않은 RSU� 보유하고 있습니다.
  • 시장 � 매매� 없었으며, 모든 활동은 자동 RSU 정산(거래 코드 “M�)� 관련되� 있습니다.

이번 제출은 임의 매수가 아닌 정기적인 주식 보상 이벤트임� 나타냅니�. COO� 지분이 소폭 증가했으� 경제� 지출은 전혀 �으므� 외부 투자자에� 주 신호� 대체로 중립�입니�.

Monopar Therapeutics (MNPR) � Transaction d'initié Formulaire 4 déposée pour le Directeur des opérations Andrew Cittadine concernant l'activité du 30 juin 2025.

  • 6 863 actions ordinaires ont été attribuées à Cittadine lors du vesting des Restricted Stock Units (RSU) accordées les 2 février 2022, 1 février 2023 et 4 mars 2025.
  • 2 990 actions ont été retenues pour impôts (code transaction « F »), laissant un net de 3 873 nouvelles actions.
  • La détention directe d'actions ordinaires de Cittadine après les transactions est de 45 858 actions ; il conserve également 43 001 RSU non acquises.
  • Aucun achat ou vente sur le marché ouvert n'a eu lieu ; toute l'activité concerne le règlement automatique des RSU (code transaction « M »).

Le dépôt indique un événement de rémunération en actions de routine plutôt qu'un achat discrétionnaire. Bien que la participation du COO augmente modestement, la dépense économique est nulle ; par conséquent, le signal pour les investisseurs externes est généralement neutre.

Monopar Therapeutics (MNPR) � Form 4 Insider-Transaktion eingereicht für Chief Operating Officer Andrew Cittadine bezüglich der Aktivität am 30. Juni 2025.

  • 6.863 Stammaktien wurden Cittadine bei der Vesting von Restricted Stock Units (RSUs) zugeteilt, die am 2. Feb 2022, 1. Feb 2023 und 4. März 2025 gewährt wurden.
  • 2.990 Aktien wurden zur Steuerabführung einbehalten (Transaktionscode „F�), wodurch netto 3.873 neue Aktien verbleiben.
  • Cittadines direkter Stammaktienbestand nach den Transaktionen beträgt 45.858 Aktien; er hält zudem 43.001 unverfallbare RSUs.
  • Es fanden keine Käufe oder Verkäufe am offenen Markt statt; alle Aktivitäten beziehen sich auf die automatische RSU-Abwicklung (Transaktionscode „M�).

Die Meldung weist auf ein routinemäßiges Aktienvergütungsereignis hin und nicht auf einen diskretionären Kauf. Obwohl der Anteil des COO leicht steigt, ist der wirtschaftliche Aufwand null; daher ist das Signal für externe Investoren im Allgemeinen neutral.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Del Preto Joseph

(Last) (First) (Middle)
131 SOUTH DEARBORN ST.
SUITE 700

(Street)
CHICAGO IL 60603

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Sprout Social, Inc. [ SPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO and Treasurer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/01/2025 S 1,500 D $21.077(1) 248,512(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.64 to $21.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The total reported in column 5 includes: (1) 6,574 reported RSUs which vest in 3 equal quarterly installments beginning on September 1, 2025; (2) 17,777 reported RSUs which vest in 7 equal quarterly installments beginning on September 1, 2025; (3) 37,897 reported RSUs which vest in 11 equal quarterly installments beginning on September 1, 2025; and (4) 118,613 reported RSUs of which 25% will vest on March 1, 2026 with the remaining RSUs vesting in 12 equal quarterly installments beginning on June 1, 2026. Each RSU represents the contingent right to receive one share of Class A Common Stock of the Issuer and does not expire.
Remarks:
The transaction in this Form 4 occurred under a 10b5-1 plan adopted by the Reporting Person on August 20, 2024.
/s/ Heidi Jonas, Attorney-in-fact for Joseph Del Preto 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MNPR shares did COO Andrew Cittadine acquire on 30 June 2025?

He received 6,863 common shares upon RSU vesting.

What is Cittadine’s total direct MNPR shareholding after the Form 4 transactions?

His direct holding is 45,858 shares of common stock.

Were any shares sold on the open market?

No. All activity relates to automatic RSU settlement; there were no open-market sales or purchases.

How many unvested RSUs does Cittadine still hold?

He retains 43,001 Restricted Stock Units scheduled to vest through 31 Dec 2028.

Did the insider pay cash to acquire these shares?

No cash was paid; shares were issued upon vesting, with 2,990 shares withheld to cover taxes.

Is this Form 4 filing considered material for MNPR investors?

The filing reflects routine compensation vesting; it is generally viewed as not materially impactful to MNPR’s valuation.
Sprout Social Inc

NASDAQ:SPT

SPT Rankings

SPT Latest News

SPT Latest SEC Filings

SPT Stock Data

1.22B
51.06M
2.47%
102.48%
7.85%
Software - Application
Services-prepackaged Software
United States
CHICAGO